RESUMO
BACKGROUND: Radioiodine therapy (131I) is a standard procedure in the treatment of hyperthyroidism in the course of Graves' disease or toxic nodules. However, the use of 131I in patients with low radioiodine uptake (RAIU) may be controversial. OBJECTIVES: To determine the influence of lithium carbonate (Li) on iodine kinetics. MATERIAL AND METHODS: Patients with hyperthyroidism and low RAIU (< 30%) were divided into 2 groups: a Li(-) group of 305 patients not receiving Li adjuvant therapy and a Li(+) group of 264 patients receiving adjuvant therapy. The serum concentrations of free triiodothyronine (fT3), free thyroxine (fT4) and thyroid stimulating hormone (TSH) were assessed at baseline, 24 h, 48 h, 72 h and 96 h, and 1, 6 and 12 months after 131I therapy. The RAIU was assessed after 5 h, 24 h, 48 h, 72 h, and 96 h. RESULTS: Levels of fT3 in the Li(+) group compared to the Li(-) group were significantly higher at baseline, lower after 48 h, 72 h, 96 h and 1 month, and did not differ significantly after 24 h, 6 months and 12 months. Levels of fT4 in the Li(+) group compared to the Li(-) group were significantly higher at baseline, lower after 24 h, 48 h, 72 h, 96 h and 1 month, and not differ significantly after 6 and 12 months. The RAIU in the hyperthyroidism Li(-) and Li(+) groups, respectively, was 11.9 ±5.6% compared to 23.9 ±10.1% (p < 0.001) after 5 h; 25.9 ±8.3% compared to 40.5 ±12.4% (p < 0.05) after 24 h; 7.8 ±8.1% compared to 40.9 ±13.7% (p < 0.05) after 48 h; 26.2 ±10.2% compared to 39.5 ±11.2% (p < 0.01) after 72 h; and 24.7 ±7.1% compared to 37.4 ±10.1% (p < 0.01) after 96 h. CONCLUSIONS: Adjuvant therapy with Li in patients with hyperthyroidism caused a significant increase in RAIU and positive changes in the fT3 and fT4 profiles. The use of lithium carbonate prior to the inclusion of 131I in hyperthyroid patients with low RAIU should be considered.
Assuntos
Hipertireoidismo , Radioisótopos do Iodo , Contraindicações , Humanos , Hipertireoidismo/tratamento farmacológico , Hipertireoidismo/radioterapia , Radioisótopos do Iodo/uso terapêutico , TireotropinaRESUMO
INTRODUCTION: Autoimmune reactions in Graves' disease (GD) occur not only in the thyroid gland, but also in the orbital connective tissue, eyelids, extraocular muscles. The occurrence of orbitopathy in the course of GD is influenced by environmental factors, e.g. cigarette smoking. OBJECTIVES: The aim of the study was to analyze the effect of cigarette smoking on the efficacy of activity of radioiodine(131I) therapy in patients with GD. We also studied the influence of cigarette smoking and the efficacy of prednisone prophylaxis on the risk of thyroid-associated ophthalmopathy (TAO) development after radioiodine therapy (RIT) during two years of follow-up. PATIENTS AND METHODS: Medical records of hyperthyroid patients treated with radioiodine had been included. Patients were scheduled to visit outpatient clinics at baseline and 1, 3, 6, 9, 12, 18, and 24 months after RIT. RESULTS: The studied group consisted of 336 patients (274 women, 62 men) diagnosed with GD and treated with RIT; 130 patients received second therapeutic dose of 131I due to recurrent hyperthyroidism. Among all studied patients, 220 (65.5%) were smokers and 116 (34.5%) non-smokers. In the group of smokers 115 (52.2%) of patients received single RIT, 105 (47.8%) received second dose of RAI due to recurrent hyperthyroidism. In non-smokers 91 (78.6%) received single activity of RAI, while 25 (21.4%) patients required second RIT due to recurrent hyperthyroidism. The ophthalmic symptoms in the group of smokers after RIT were less frequent, if the patient received preventative treatment in the form of oral prednisone (P = 0.0088). CONCLUSIONS: The results of our study suggest that cigarette smoking reduces the efficacy of treatment with 131I in patients with GD. The study also confirmed the effectiveness of steroid prophylaxis against TAO development or exacerbation after RIT.
Assuntos
Doença de Graves/radioterapia , Compostos Radiofarmacêuticos/uso terapêutico , Adulto , Idoso , Anti-Inflamatórios/uso terapêutico , Fumar Cigarros , Feminino , Doença de Graves/tratamento farmacológico , Oftalmopatia de Graves/diagnóstico , Oftalmopatia de Graves/tratamento farmacológico , Humanos , Hipertireoidismo/diagnóstico , Hipertireoidismo/patologia , Radioisótopos do Iodo/química , Radioisótopos do Iodo/metabolismo , Masculino , Pessoa de Meia-Idade , Prednisona/uso terapêutico , Compostos Radiofarmacêuticos/química , Compostos Radiofarmacêuticos/metabolismo , Recidiva , Estudos Retrospectivos , Tireotropina/sangue , Tiroxina/sangue , Tri-Iodotironina/sangue , Adulto JovemRESUMO
PURPOSE: The aim of this study was to evaluate the association between vitamin D (vitD) and changes in the titers of anti-TSH receptor (TSHR-Abs), antithyroglobulin (Tg-Abs), and antiperoxidase (TPO-Abs) autoantibodies. MATERIALS/METHODS: The study involved 269 patients with Graves' disease (GD), divided into four subgroups (1-4), i.e. 65 smokers treated with vitD(+) (1), 76 smokers not treated with vitD(-) (2), 61 non-smokers treated with vitD(+) (3) and 67 non-smokers with vitD(-) (4). All thyroid parameters were analyzed at entry and 1, 3, 6, 9 and 12 months later. RESULTS: The titer of TSHR-Abs in group 3 was significantly lower than in groups 1 and 2 across all time points. At 3, 6 and 12 months, the titers of TSHR-Abs were also lower in group 4 compared to groups 1 and 2. At 9 months, the titers in group 3 were lower than in all other groups. There was a significant inverse correlation between baseline levels of vitD and baseline titers of Tg-Abs (in group 1 only), Tg-Abs after 12 months (in group 1 only), TPO-Abs after 12 months (in groups 1 and 3), fT4 (in group 4 only), and a significant positive correlation with TPO-Abs (in group 2 only). VitD levels at 12 months were inversely correlated with Tg-Abs in group 1. CONCLUSIONS: VitD measurements in patients with GD, especially smokers with an increased TSHR-Ab titers before 131I therapy, are recommended. Immunological remission is more likely in patients with GD who receive vitD, particularly smokers.
Assuntos
Autoanticorpos/sangue , Autoantígenos/imunologia , Doença de Graves/patologia , Radioisótopos do Iodo/uso terapêutico , Deficiência de Vitamina D/complicações , Vitamina D/sangue , Adulto , Autoanticorpos/imunologia , Feminino , Seguimentos , Doença de Graves/epidemiologia , Doença de Graves/imunologia , Doença de Graves/radioterapia , Humanos , Masculino , Pessoa de Meia-Idade , Prognóstico , Receptores da Tireotropina/imunologia , Estudos Retrospectivos , Tireoglobulina/imunologia , Tireotropina/imunologia , Vitamina D/imunologiaRESUMO
INTRODUCTION Graves ophthalmopathy (GO) is an autoimmune disease associated with Graves disease. Its treatment is largely dependent on the severity and activity of ocular lesions. Particular attention should be given to radioiodine (RAI) therapy. Although its use is a valuable therapeutic option for hyperthyroidism, it may be followed by worsening of GO. OBJECTIVES The aim of the present study was to analyze how the severity of nicotine addiction affects the response to RAI treatment in patients with GO. PATIENTS AND METHODS A total of 106 patients (58 smokers and 48 nonsmokers) with mild GO treated with 800 MBq of RAI were included to the study. We assessed the serum levels of thyroidstimulating hormone (TSH), thyroid hormones, autoantibodies against thyroperoxidase, thyroglobulin, and TSH receptor (TSHRAbs), as well as urinary cotinine levels and severity of ophthalmopathy. Analyses were conducted at baseline (before RAI treatment) and 2 and 6 months after the therapy. RESULTS Significant differences in serum levels of TSHRAbs were found between nonsmokers and smokers at 2 and 6 months after RAI therapy, whereas there were no differences at baseline. In smokers, there were significant differences in the severity of ophthalmopathy and the concentration of serum TSHRAbs assessed at baseline and at 6 months of followup. Six months after RAI therapy, 46.2% of smokers and 4.3% of nonsmokers (P <0.001) progressed from mild to moderate GO. CONCLUSIONS High urinary cotinine levels in smokers were associated with the deterioration of ocular lesions after RAI treatment. A high dose of RAI did not induce an exacerbation of GO in nonsmokers who were administered oral steroid prophylaxis.
Assuntos
Oftalmopatia de Graves/radioterapia , Radioisótopos do Iodo/uso terapêutico , Fumar , Adulto , Cotinina/urina , Feminino , Seguimentos , Oftalmopatia de Graves/sangue , Oftalmopatia de Graves/urina , Humanos , Masculino , Radioterapia/efeitos adversos , Hormônios Tireóideos/sangue , Tireotropina/sangue , Resultado do TratamentoRESUMO
OBJECTIVES: Radioiodine therapy (RIT) is frequently used as the definitive treatment in patients with Graves' hyperthyroidism when remission is not achieved with anti-thyroid drugs (ATDs). In this observational study, we intended to examine whether the use of high doses of radioiodine (RAI) [22 mCi (814 MBq)] with prophylaxis of oral glucocorticoids (oGCS) does not exacerbate Graves ophthalmopathy (GO) in smokers and non-smokers, especially regards to the urine level cotinine and ocular changes before and after RIT. PATIENTS AND METHODS: The studied group consisted of 26 smokers, aged 28-61 years and 25 non-smoker patients, aged 21-54 years, respectively. The patients were enrolled to RAI after one-year of ineffective ATDs treatment. Criterion for inclusion in the study were patients with mild GO with hyperthyroidism at diagnosis based on the severity (NOSPECTS) and activity (CAS) scale. All the patients were subjected to RIT with oGCS prophylaxis and evaluated prospectively during a one-year follow-up. The ophthalmological examination was performed at various stages of RIT: initial pre-radioiodine administration, at the time of treatment 6, and 12 months after RAI. The present study is unique, because the urine cotinine measurement was employed to detect nicotine exposure, also in regard to smoking intensity. RESULTS: In smokers, the values of serum TPO-Abs were statistically significant in the second and six month (p<0.05) and in the second and after one year (p<0.005). The TSHR-Abs concentration was significantly higher in smokers (p<0.05), rising from 22.9±1.2 IU/L before therapy to 29.6±5.3 IU/L - 2 months, 32.6±8.6 IU/L - 6 months, and slightly decreased 28.9±10.6 IU/L - 12 months. These observed changes were statistically different between groups at baseline (p<0.05) and after one-year of follow-up (p<0.005). Mean urine cotinine were considerably higher in smokers comparing to non smokers in each point of observation [903.4±770.0 and 5.2±1.7 ng/mL at baseline (p<0.001), 412.8±277.3 and 3.0±0.6 ng/mL after 2 months (p<0.001), 452.0±245 and 6.6±3.6 after 6 months (p<0.001), 379.4±236.8 and 1.0±1.2 after one year (p<0.001)]. The CAS values in the smoking group before RIT increased statistically from 2.8±0.2 points at baseline to 4.3±0.3 after 6 months, and 4.0±0.5 (12 months), while in the non-smoking patients it was 1.4±0.2, 2.8±0.3 and 2.2±0.2, respectively. The level of urine cotinine correlated positively with CAS and TSHR-Ab in the smoking group (r=0.41; p<0.05) at baseline and during follow-up (2 months: r=0.46; p<0.001, 6 months: r=0.47, p<0.005; 12 months: r=0.46; p<0.005). In the NOSPECS classification, the symptoms changed from mild to moderate, mostly in smoking patients. CONCLUSIONS: 1) ablative RIT dose with prophylactic oral prednisone is a safe treatment in both smokers and non-smokers with mild GO; 2) The post hoc analysis showed that urinary level of cotinine can be very helpful in the assessment of exacerbation of ophthalmological clinical symptoms before and after RIT particularly in smokers.
Assuntos
Quimiorradioterapia/métodos , Cotinina/urina , Oftalmopatia de Graves/metabolismo , Oftalmopatia de Graves/terapia , Prednisolona/administração & dosagem , Fumar , Adulto , Quimiorradioterapia/efeitos adversos , Relação Dose-Resposta à Radiação , Feminino , Glucocorticoides/administração & dosagem , Humanos , Masculino , Pessoa de Meia-Idade , Nicotina/farmacocinética , Agonistas Nicotínicos/farmacocinética , Testes de Função Tireóidea , Transtornos da Visão/diagnóstico , Transtornos da Visão/etiologia , Adulto JovemRESUMO
Eisenmenger's syndrome is a condition due to any congenital heart defect with an intracardiac left-to-right communication that leads to pulmonary hypertension with reversed right-to-left blood flow and secondary cyanosis. The main complications of Eisenmenger's syndrome are heart failure and arrhythmias. Amiodarone, the drug of choice for arrhythmia treatment in such patients, can cause a number of complications, including amiodarone induced thyrotoxicosis (AIT). Hereby, we present a 41-year-old patient with Eisenmenger's syndrome who developed AIT and was successfully treated with radioactive iodine therapy. The patient had an accompanying heart failure and had been treated with amiodarone due to chronic atrial fibrillation. Twenty months later he developed an AIT for which was treated with 814 MBq (22 mCi) radioactive iodine. Since 7 weeks later only a slight decline in thyroid hormones was observed, the patient was received a transient treatment with methimazole, which had to be withdrawn soon due to severe leucopenia. Because of the need to maintain amiodarone, a second ablative radioactive iodine dose was administered leading to complete clinical remission. In conclusion, this case demonstrates that even though amiodarone reduces iodine uptake to a very low level, the therapy with radioactive iodine can be still effective if it is given in a repeated dose to patients who require continuation of amiodarone.
Assuntos
Amiodarona/efeitos adversos , Antiarrítmicos/efeitos adversos , Fibrilação Atrial/tratamento farmacológico , Complexo de Eisenmenger/tratamento farmacológico , Tireotoxicose/induzido quimicamente , Adulto , Humanos , Radioisótopos do Iodo/uso terapêutico , Masculino , Tireotoxicose/radioterapia , Resultado do TratamentoRESUMO
BACKGROUND: Conventional management of Interferon-α-Induced Hyperthyroidism (IIH) with radioactive iodine (RAI) may be used when treatment with beta blockers or antithyroid drugs (ATD), proves ineffective or is contraindicated. CASE PRESENTATION: We present a 38-year-old woman who has been treated with combined pegylated interferon alpha (INF-α) and Ribavirin for chronic hepatitis C. Destructive thyrotoxicosis appeared after four months of continuous IFN-α therapy and a beta blocker was prescribed. Initially, the patient presented normal TSH 2.4 µIU/mL, however during therapy with INF-α, TSH diminished to 0.05 and thyroid hormones were elevated: fT4 23.1 pmol/L, fT3 7.2 pmol/L. Ultrasound examination showed completely irregular and greatly decreased echogenicity of the thyroid gland. The radioiodine uptake (RAIU) was deeply decreased to 2 and 3% at 5 h and 24 h, respectively. The thyroid scintiscan showed lack of isotope accumulation. Hypothyroidism developed and L-thyroxine was prescribed. The following year, hyperthyroidism reoccurred with TSH 0.08 µIU/mL, fT4 26.4 pmol/L, fT3 8.2 pmol/L, positive TSHR-Abs 6.2 (normal <2 IU/L) and mild Graves' Ophthalmopathy (GO). RAIU values were 23% at 5 h and 46% at 24 h. Thyroid scintiscan showed diffuse goiter. At this point beta blocker was introduced and ATD was started. After three months of therapy an increased level of aminotransferases and granulocytopaenia were observed. Hence, the patient received RAI and glucocorticosteroid, while INF-α therapy was continued. After approximately 4 months, hypothyroidism reappeared with insignificantly raised TSH level. One year later the patient was euthyroid and required no further treatment. CONCLUSIONS: Our report suggests that: 1. Radioiodine therapy might be an effective and safe method of treatment in cases of IIH with mild GO. 2. IFN-α therapy need not be discontinued in patients with IIH.
Assuntos
Agranulocitose/radioterapia , Hepatite C Crônica/tratamento farmacológico , Hipertireoidismo/induzido quimicamente , Hipertireoidismo/radioterapia , Interferon-alfa/efeitos adversos , Transaminases/sangue , Adulto , Antivirais/efeitos adversos , Feminino , Humanos , Hipertireoidismo/sangue , Hipotireoidismo/sangue , Hipotireoidismo/tratamento farmacológico , Radioisótopos do Iodo/uso terapêutico , Tireotropina/sangueRESUMO
This paper presents the current state of knowledge on the treatment of ophthalmopathy in the process of the Grave's disease. The question of prevention occupies a special place in the process of treatment as it has been clearly shown that exophthalmos is strongly associated with cigarette smoking. Therefore, before proceeding with any treatment, the patient should be advised to quit smoking as soon as possible. Further on in the publication, various forms of therapy are presented. Because of the unknown etiology, only symptomatic treatment can be applied, which includes steroids, radiotherapy and surgery. Patient care of patients with ophthalmopathy is a challenge even for an experienced clinician. Each case requires an individual approach that would take into account the severity of eye changes.
Assuntos
Oftalmopatia de Graves/etiologia , Oftalmopatia de Graves/prevenção & controle , Fumar/efeitos adversos , Glucocorticoides/efeitos adversos , Glucocorticoides/uso terapêutico , Doença de Graves/tratamento farmacológico , Doença de Graves/radioterapia , Doença de Graves/cirurgia , Humanos , Radioisótopos do Iodo/efeitos adversos , Complicações Pós-Operatórias/etiologia , Complicações Pós-Operatórias/prevenção & controle , Radioterapia/efeitos adversos , Prevenção do Hábito de FumarRESUMO
Perinatal brachial plexus palsy (PBPP) constitutes a serious medical problem. PBPP treatment consists in conservative and operative procedures. The latter one is usually divided into primary operative procedures, conducted in the initial stage of child's life (aiming at suture of brachial plexus nerves in the early stage of life) and secondary (aiming at elimination of functional limitations, osseous deformations, articular contractures occuring at later stages of life). A significant but also controversial aspect arises at determining the date of operation performance and also at defining factors classifying a child for surgical operation and details concerning the application of definite operative method. The following microsurgical methods are applied in microsurgical reconstruction of PBPP: neurolysis (external and internal), end-to-end nerve suture, free nerve grafts. The most complicated are injuries which result in root avulsion from the spinal medulla. In such cases the avulsed roots are connected to nerves of cervical plexus, applying the method of neurotization. The reason of numerous controversies around the choice of treatment method for PBPP patients is the desire to balance procedures aiming at the proper functioning of the patient in future.
Assuntos
Traumatismos do Nascimento/cirurgia , Neuropatias do Plexo Braquial/cirurgia , Plexo Braquial/cirurgia , Microcirurgia/métodos , Traumatismos do Nascimento/etiologia , Plexo Braquial/lesões , Neuropatias do Plexo Braquial/etiologia , Criança , Humanos , Recém-Nascido , Transferência de Nervo/métodos , Procedimentos de Cirurgia Plástica/métodosRESUMO
Apart from the possibilities to predict and eliminate the risk factors (especially in highly developed countries) the perinatal brachial plexus palsy (PBPP) still constitutes severe labor complications. PBPP treatment may be divided into conservative and operative categories. It is considered that the time necessary to regain functioning of brachial and ulnar articulations in children with BPPP (treated conservatively and surgically) amounts to 2 years approximately. Therefore, second late surgical technique of muscles and tendons of paralysed limb is performed in children at this age and older. It is accompanied by orthopaedic treatment and therapeutic rehabilitation, the aim of which is the improvement of its efficiency. The choice of proper treatment method (especially when chronic paralysis is observed) is conditioned by disorders of functioning in particular parts of a limb. Most frequently detected impairments resulting from BPPP which are treated surgically are disorders of shoulder functioning which occurs in 50% of plexus palsies. Ulnar dysfunctions constitute 15%, forearm dysfunctions amount to 15% and finally hand dysfunction is equal to 10%. Dysfunctioning of the upper limb constitutes 10%. Its reconstruction procedure is not necessary. The positive aspect of surgical reconstruction in patients with PBPP is not only improvement of paralysed limb functioning but also of patient's self-evaluation.
Assuntos
Neuropatias do Plexo Braquial/cirurgia , Paralisia/prevenção & controle , Neuropatias do Plexo Braquial/complicações , Cotovelo/fisiopatologia , Cotovelo/cirurgia , Humanos , Lactente , Recém-Nascido , Paralisia/etiologia , Paralisia/reabilitação , Assistência Perinatal , Procedimentos de Cirurgia Plástica , Reoperação , Ombro/fisiopatologia , Ombro/cirurgiaRESUMO
INTRODUCTION: Orbitopathy associated with Graves' disease TAO (thyroid associated orbitopathy) is likewise connected with environmental factors including tobacco smoking. Tobacco smoking increases the risk of ophthalmologic pathology and leads to the orbital tissue damage due to the hypoxia. The aim of the study was to correlate the concentration of urinecotinine (marker of tobacco smoking) in Graves' disease patients with TAO with points received on the Fagerström questionnaire. MATERIALS AND METHODS: Thirty women with different degree of exacerbation of TAO in Graves' disease (34.28 +/- 12.04 yr.) were examined. As control we used 29 women with Graves' disease without TAO (29.35 +/- 12.33 yr.). The diagnosis was established according to level of TSH and level of thyrotropin receptor antibodies (TRAb). Measure of tobacco smoking or exposure to second hand tobacco smoke ETS (environmental tobacco smoke) carried out according to the Fagerström questionnaire, and measured cotinine level (the major metabolite of nicotine in urine). The level of clinical ophtalmopathy was measured according to the CAS (Clinical Activity Score) scale and degree of progression of TAO according to American Thyroid Association (NOSPECS scale). Additionally increase of exophthalmus was measured using the Hertl's exophthalmometer. RESULTS: In the group with TAO: 19 (63.3%) persons had mild exophthalmos (according to CAS), medium in 13 (43.3%) patients, and pronounced exophthalmous in 10 (33%) patients. There was statistically significant difference in the level of TRAb (18.4 +/- 8.2 vs. 5.1 +/- 3.4 IU/l; p < 0.0001) between TAO and controls. There was no correlation between TSH (0.6 +/- 0.02 vs. 0.4 +/- 0.04; p = 0.18) and fT4 (38.8 +/- 29.3 vs. 26.1 +/- 17.3; p = 0.026) in both analyzed groups. Smokers and non-smokers with TAO had no statistically significant in level of TRAb (Mann-Whitney test p = 0.16). No correlation was found between smoking tobacco (cotinine level) and the level of TRAb in patients with TAO (Pearson r = 0.28 p = 0.58). There was a statistically significant difference between the level of urine cotinine in smoking patients with TAO in the highest level of ophthalmopathy exacerbation (> 24 mm; > or = 4 points according to CAS) and those without TAO (Mann-Whitney's test p = 0.04). CONCLUSIONS: 1. In patients with Graves' disease with TAO the highest score of tobacco smoking has been found in persons with the highest ophthalmopathy exacerbation. 2. Estimation of cotinine concentration in urine is the most objective and useful method of tobacco smoking.